Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial

Blood Cancer J. 2023 Jan 11;13(1):10. doi: 10.1038/s41408-022-00771-w.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Multicenter Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / prevention & control
  • Hematologic Neoplasms* / drug therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Prospective Studies
  • Retrospective Studies
  • Transplantation Conditioning

Substances

  • Antilymphocyte Serum
  • Cyclophosphamide